Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OPB 51602

Drug Profile

OPB 51602

Alternative Names: OPB-51602

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Multiple myeloma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 18 Jun 2015 National University Hospital in collaboration with Otsuka and Shin Nippon terminates a phase I trial in Nasopharyngeal cancer (Late-stage disease) in Singapore (NCT02058017)
  • 01 Apr 2014 Otsuka Pharmaceutical completes a phase I trial in Multiple myeloma, Non-Hodgkin lymphoma, Acute myeloid leukaemia, Acute lymphoid leukaemia, Chronic myeloid leukaemia (Second-line therapy or greater) in Japan (NCT01344876)
  • 17 Feb 2014 Phase 1 development is ongoing the USA, Singapore and Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top